Medtech dealmaking has been active. PwC counted $97.6 billion in medtech deal value in 2025, a decade high, and $36.5 billion in the first half of 2026, running above the first half of 2025. Large transactions such as Boston Scientific's agreement to acquire Penumbra, announced in January 2026, sit alongside competitive processes for smaller assets, and competitive processes put pressure on diligence timelines.
A compressed timeline tends to cover what is quick to check and skip what takes time. What gets missed can surface after close as manufacturing bottlenecks, reimbursement changes, regulatory findings, cybersecurity liabilities or legal contingencies.
Why Acquirers Are Buying
Common deal rationales each carry a characteristic diligence challenge:
- Pipeline acquisition: buying earlier-stage companies to fill future pipelines. The challenge is judging which products will actually generate returns.
- Platform consolidation: combining companies in the same disease area. Integrating sales forces, manufacturing and regulatory files is often slower and harder than planned.
- Operational improvement: private equity buyers acquiring profitable niche devices and applying operational leverage. Payment and coverage can change as volume grows.
- Adjacency expansion: entering segments the buyer does not already serve, as Stryker described its Inari acquisition and Abbott its Exact Sciences acquisition (see our 2025 M&A review). The clinical, regulatory and commercial competencies needed may not transfer.
Each of these calls for diligence that goes past the data room summary.
What Compressed Diligence Can Miss
| What a Compressed Review Usually Covers | What It Can Miss |
|---|---|
| Regulatory status and timeline | Postmarket obligations, complaint and adverse event trends |
| Manufacturing cost structure | Scalability limits and process capability when volume increases |
| Revenue and customer base | Customer concentration and reimbursement risk |
| IP and patent landscape | Freedom-to-operate risk from competitor patents |
| Management team capability | Organizational fragility and key-person dependencies |
| Current financial performance | Sustainability of growth and margin assumptions after acquisition |
| Payer relationships | Coverage decision timelines and denial patterns |
| Cybersecurity posture | Legacy vulnerabilities, compliance gaps and incident history |
An Example of the Pattern (Illustrative)
A hypothetical: a device company shows it can manufacture 50,000 units a year, and the buyer's model assumes linear scaling to 200,000. If the process hits constraints well short of that, from equipment limits, supplier dependencies or change control requirements, the buyer may learn it only when post-close growth targets are missed.
Platform vs. Bolt-On: Different Diligence Depth
Medtech acquisitions are often grouped into platform acquisitions (buying a company to build a portfolio around) and bolt-on acquisitions (adding complementary products to an existing platform). They call for different depth:
Platform Acquisitions
When a buyer acquires a company as a platform for later acquisitions, the commercial strategy depends on it, so diligence needs to go deeper:
- Detailed manufacturing scalability analysis
- Market dynamics and competitive position
- Whether adjacency expansion is viable
- Integration risk across functions
Bolt-On Acquisitions
When a buyer adds a complementary product to an existing sales force or manufacturing platform, diligence can be more focused:
- Customer overlap and revenue attribution
- Regulatory and compliance obligations
- Manufacturing integration and cost impact
- Reimbursement and payer relationships
The risk is that a platform deal gets bolt-on-length diligence, which leaves blind spots exactly where the commercial strategy depends most on the target.
Long-Tail Risks That Get Missed
Manufacturing Scalability
Some companies that manufacture reliably at their current scale hit constraints when volume rises. Finding them takes process engineering analysis, not only cost accounting, and a short review may not get that far; see our manufacturing due diligence questions.
Reimbursement Changes
A device can be profitable in a niche because payment is favorable for a small patient population. As use grows, payers may revisit coverage or payment. Seeing that risk takes coverage-policy and payer-level analysis, not only historical revenue; see our reimbursement red flags.
Postmarket Obligations
Device manufacturers must report certain adverse events to FDA, generally within 30 calendar days of becoming aware of them (21 CFR 803.50), and FDA can order postmarket surveillance of certain Class II and Class III devices under section 522 of the Federal Food, Drug, and Cosmetic Act. A target's complaint history, adverse event reports, recalls and any open postmarket study obligations can mean higher compliance costs than a quick review assumes.
Cybersecurity
For connected devices, section 524B of the Federal Food, Drug, and Cosmetic Act makes cybersecurity documentation part of premarket submissions for cyber devices, and postmarket vulnerability management is an ongoing obligation. A surface-level review can miss unsupported software components or unpatched vulnerabilities; see our cybersecurity article.
Contingent Liabilities
Regulatory, legal and product liability contingencies can be partly disclosed or not disclosed at all, and a short timeline limits how far legal diligence can go. Warning letters, recalls and litigation are among the items worth checking against public records; see verifying medtech claims against the public record.
The Second-Opinion Model
One way to protect quality on a tight timeline is a second-opinion model:
- The internal diligence team runs its standard review
- A third-party specialist (a manufacturing engineer, reimbursement analyst or regulatory expert) runs a targeted deep dive on the highest-risk areas
- The results are combined to flag risks the internal team may have missed under time pressure
This adds time, but for a large acquisition a short extension to examine the highest-risk areas can cost far less than a post-close surprise; see clinical and engineering risk in medtech deals.
Where Vantage Fits
Vantage's M&A Report ($25,000, within 48 hours of a complete intake) is built for this: diligence reviewed by a physician and a biomedical engineer, with each factual claim cited to its source, plus integration risk and reference-contact review and a 60-minute strategy session. It reads a target's manufacturing, regulatory and reimbursement record alongside the deal materials.
References
- MedTech Dive. "Medtech M&A maintains momentum following decade-high 2025: PwC." June 17, 2026. medtechdive.com
- Boston Scientific. "Boston Scientific announces agreement to acquire Penumbra, Inc." January 15, 2026. news.bostonscientific.com
- 21 CFR 803.50, "Individual adverse event reports; manufacturers." law.cornell.edu
- FDA. "522 Postmarket Surveillance Studies Program." fda.gov
- FDA. "Cybersecurity." Digital Health Center of Excellence. fda.gov
De-Risk Your M&A Process
A full Vantage report reads a target's manufacturing, reimbursement and regulatory record alongside the deal materials, cited to its sources, with a 48-hour turnaround.